| Company/Division name | Manus |
| Parent company | Manus Bio Inc. |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2026 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 15 |
| City reshored to: | Augusta |
| State(s) reshored to: | GA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | shikimic acid for Tamaflu |
| What non-domestic negative factors made offshoring less attractive? | Supply chain interruption |
| What domestic positive factors made reshoring more attractive? | Government Incentives, Impact on domestic economy, Skilled workforce availability/training |
| Government Incentive dollar amount: | 15,000,000 grant from DHS |
